HC Wainwright restated their buy rating on shares of LAVA Therapeutics (NASDAQ:LVTX – Free Report) in a research report sent to investors on Friday morning, Marketbeat.com reports. They currently have a $6.00 price target on the stock.
LAVA Therapeutics Price Performance
Shares of NASDAQ LVTX opened at $1.87 on Friday. LAVA Therapeutics has a 1-year low of $1.13 and a 1-year high of $6.47. The company has a quick ratio of 7.42, a current ratio of 7.42 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $2.50 and a two-hundred day moving average of $2.34.
LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) last announced its earnings results on Tuesday, May 21st. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.23. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%. The company had revenue of $6.99 million during the quarter. On average, equities research analysts expect that LAVA Therapeutics will post -1.3 earnings per share for the current year.
Hedge Funds Weigh In On LAVA Therapeutics
About LAVA Therapeutics
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Featured Stories
- Five stocks we like better than LAVA Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Healthcare Dividend Stocks to Buy
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is the Dow Jones Industrial Average (DJIA)?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.